{
  "ticker": "AVIR",
  "company_name": "Atea Pharmaceuticals, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05629962",
      "title": "SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19",
      "start_date": "2022-11-25",
      "completion_date": "2024-05-30",
      "enrollment": 0,
      "sponsor": "Atea Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT05724693",
      "title": "Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteer, Hepatic Impairment",
      "start_date": "2023-01-30",
      "completion_date": "2024-04-23",
      "enrollment": 0,
      "sponsor": "Atea Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT07272889",
      "title": "Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)",
      "status": "NOT_YET_RECRUITING",
      "phase": "PHASE1",
      "condition": "Healthy Volunteer Study",
      "start_date": "2025-12",
      "completion_date": "2025-12",
      "enrollment": 0,
      "sponsor": "Atea Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04019717",
      "title": "Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Hepatitis C, Hepatitis C, Chronic, Chronic Hepatitis C, Hepatitis C Virus Infection, HCV Infection",
      "start_date": "2019-06-20",
      "completion_date": "2020-03-23",
      "enrollment": 0,
      "sponsor": "Atea Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04784000",
      "title": "Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteer Study",
      "start_date": "2021-03-01",
      "completion_date": "2021-04-10",
      "enrollment": 0,
      "sponsor": "Atea Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT05904470",
      "title": "A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C, Hepatic Cirrhosis, HCV",
      "start_date": "2023-05-30",
      "completion_date": "2025-01-28",
      "enrollment": 0,
      "sponsor": "Atea Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04709835",
      "title": "Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "COVID-19",
      "start_date": "2021-02-03",
      "completion_date": "2021-10-13",
      "enrollment": 0,
      "sponsor": "Hoffmann-La Roche"
    },
    {
      "nct_id": "NCT05154123",
      "title": "Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteer Study",
      "start_date": "2021-11-16",
      "completion_date": "2021-12-23",
      "enrollment": 0,
      "sponsor": "Atea Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT06921941",
      "title": "Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteer Study",
      "start_date": "2025-04-08",
      "completion_date": "2025-07-02",
      "enrollment": 0,
      "sponsor": "Atea Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT06868264",
      "title": "C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "HEPATITIS C VIRUS CHRONIC INFECTION",
      "start_date": "2025-04-07",
      "completion_date": "2026-12",
      "enrollment": 0,
      "sponsor": "Atea Pharmaceuticals, Inc."
    }
  ],
  "summary": {
    "total_trials": 35,
    "by_phase": {
      "PHASE3": 4,
      "PHASE1": 24,
      "PHASE2": 5,
      "": 1,
      "PHASE1, PHASE2": 1
    },
    "by_status": {
      "COMPLETED": 24,
      "NOT_YET_RECRUITING": 2,
      "ACTIVE_NOT_RECRUITING": 1,
      "RECRUITING": 2,
      "TERMINATED": 5,
      "WITHDRAWN": 1
    },
    "active_trials": 3,
    "completed_trials": 24,
    "conditions": [
      "COVID-19",
      "COVID-19, Long COVID",
      "Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C, Hepatic Cirrhosis, HCV",
      "Chronic Hepatitis C, Hepatitis C, Hepatitis C, Chronic",
      "Dengue",
      "Dengue Fever",
      "HEPATITIS C VIRUS CHRONIC INFECTION",
      "HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C",
      "Healthy Volunteer Study",
      "Healthy Volunteer Study, Hepatic Impairment, Renal Impairment",
      "Healthy Volunteer, Hepatic Impairment",
      "Healthy Volunteer, Renal Impairment",
      "Healthy Volunteers Study",
      "Hepatitis C, Hepatitis C, Chronic, Chronic Hepatitis C, Hepatitis C Virus Infection, HCV Infection",
      "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:16:50.322596",
    "search_query": "Atea Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Atea+Pharmaceuticals,+Inc."
  }
}